Evidence map›Paper›PMID 25401926›Full record

ArticlePloS one2014

β-Arrestin-dependent deactivation of mouse melanopsin.

Evan G Cameron, Phyllis R Robinson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 28 citations in OpenAlex.

  1. Divergence of Melanopsin's Intrinsic Properties and Downstream Actions.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. The Multistable Melanopsins of Mammals.Frontiers in ophthalmology · 2023
    Article
  7. A systematic comparison of optogenetic approaches to visual restoration.Molecular therapy. Methods & clinical development · 2022
    Article
  8. Article
  9. Melanopsin phototransduction: beyond canonical cascades.The Journal of experimental biology · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Evan G CameronDepartment of Biological Sciences, University of Maryland, Baltimore County, Baltimore, Maryland, United States of America.
Phyllis R RobinsonDepartment of Biological Sciences, University of Maryland, Baltimore County, Baltimore, Maryland, United States of America.
University of Maryland, Baltimore County · US

Funding

Graduate Training at The Chemistry Biology InterfaceT32GM066706 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SELEY-RADTKE, KATHERINE L, SMITH, AARON T · 2004 to 2023
$3.3M
Molecular characterization of mouse melanopsin and second messenger pathway.R01EY019053 · NEI · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI ROBINSON, PHYLLIS R · 2009 to 2012
$1.2M
NEI NIH HHS R01 EY019053NEI NIH HHS R01EY019053NIGMS NIH HHS T32 GM066706PHS HHS NIH/NIGMS T32GM066706
6 · The paper itself

Abstract

In mammals, the expression of the unusual visual pigment, melanopsin, is restricted to a small subset of intrinsically photosensitive retinal ganglion cells (ipRGCs), whose signaling regulate numerous non-visual functions including sleep, circadian photoentrainment and pupillary constriction. IpRGCs exhibit attenuated electrical responses following sequential and prolonged light exposures indicative of an adaptational response. The molecular mechanisms underlying deactivation and adaptation in ipRGCs however, have yet to be fully elucidated. The role of melanopsin phosphorylation and β-arrestin binding in this adaptive process is suggested by the phosphorylation-dependent reduction of melanopsin signaling in vitro and the ubiquitous expression of β-arrestin in the retina. These observations, along with the conspicuous absence of visual arrestin in ipRGCs, suggest that a β-arrestin terminates melanopsin signaling. Here, we describe a light- and phosphorylation- dependent reduction in melanopsin signaling mediated by both β-arrestin 1 and β-arrestin 2. Using an in vitro calcium imaging assay, we demonstrate that increasing the cellular concentration of β-arrestin 1 and β-arrestin 2 significantly increases the rate of deactivation of light-activated melanopsin in HEK293 cells. Furthermore, we show that this response is dependent on melanopsin carboxyl-tail phosphorylation. Crosslinking and co-immunoprecipitation experiments confirm β-arrestin 1 and β-arrestin 2 bind to melanopsin in a light- and phosphorylation- dependent manner. These data are further supported by proximity ligation assays (PLA), which demonstrate a melanopsin/β-arrestin interaction in HEK293 cells and ipRGCs. Together, these results suggest that melanopsin signaling is terminated in a light- and phosphorylation-dependent manner through the binding of a β-arrestin within the retina.

Indexed as

LightAnimalsArrestinsbeta-Arrestin 1beta-Arrestin 2beta-ArrestinsBlotting, WesternCells, CulturedHEK293 CellsHumansImmunoprecipitationMelanopsinMiceMice, Inbred C57BLPhosphorylationPhotic StimulationARRB1 protein, humanArrb1 protein, mouseARRB2 protein, humanArrb2 protein, mouseArrestinsbeta-Arrestin 1beta-Arrestin 2beta-ArrestinsMelanopsinRod Opsins

Identifiers

PMID25401926
PMCPMC4234672
OpenAlexW2064875912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.